Aclaris Therapeutics, Inc. (ACRS) SEC Filing 10-Q Quarterly Report for the period ending Wednesday, June 30, 2021

Facility and support services, including general office expenses, information technology costs and other expenses, decreased during the three and six months ended June 30, 2021 compared to the three and six months ended June 30, 2020 primarily due to lower information technology costs resulting from lower headcount.

ATI-1777 The decrease in expenses for ATI-1777 during the three months ended June 30, 2021 compared to the three months ended June 30, 2020 was primarily due to lower costs associated with a Phase 2a clinical trial in subjects with moderate to severe atopic dermatitis as well as other development costs.

Other research and development expenses, which primarily include expenses for our legacy dermatology assets and medical affairs activities, were lower during the three and six months ended June 30, 2021 compared to June 30, 2020 due to a decrease in costs for our legacy dermatology assets following the decision to discontinue investment in those programs.

Financing Activities Financing activities use of cash was the result of: Proceeds from issuance of common stock in connection with public offerings, net of issuance costs 238,200 Proceeds from debt financing (including warrants), net of issuance costs 10,913 Restricted stock unit employee tax withholdings (3,038) Finance lease payments (92) Proceeds from exercise of employee stock options and the issuance of stock 1,459 Net cash provided by financing activities 236,621 10,821 Cash provided by financing activities increased for the six months ended June 30, 2021 compared to June 30, 2020 primarily due to our January 2021 and June 2021 public offerings.